3-bromo-4-(4-methylpiperazin-1-ylmethyl)benzoic acid ethyl ester | 641615-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-bromo-4-(4-methylpiperazin-1-ylmethyl)benzoic acid ethyl ester
• 英文别名: ethyl 3-bromo-4-(4-methylpiperazin-1-ylmethyl)benzoate；Ethyl 3-bromo-4-[(4-methylpiperazin-1-yl)methyl]benzoate
• CAS: 641615-27-2
• 化学式: C₁₅H₂₁BrN₂O₂
• 分子量: 341.248
• InChiKey: QIUGWZPQMHHAFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-bromo-4-(4-methylpiperazin-1-ylmethyl)benzoic acid ethyl ester 在 吡啶 、 sodium hydroxide 、 氯化亚砜 作用下， 生成 3-bromo-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide
  参考文献：
  名称：

  Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

  摘要：

  A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.042
• 作为产物：
  描述：

  3-溴-4-甲基苯甲酸 在 过氧化苯甲酰 N-溴代丁二酰亚胺(NBS) 、 硫酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 四氯化碳 为溶剂， 生成 3-bromo-4-(4-methylpiperazin-1-ylmethyl)benzoic acid ethyl ester
  参考文献：
  名称：

  Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

  摘要：

  A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.042

文献信息

• Ｂｃｒ−Ａｂｌタンパク質イメージング用分子プローブ
  申请人：国立大学法人京都大学

  公开号：JP2019064987A

  公开（公告）日：2019-04-25

  【課題】Bcr-Ablタンパク質をイメージング可能な新たな化合物の提供。【解決手段】 下記式（Ｉ）で表される化合物又はその製薬上許容される塩。【選択図】図５

  提供一种可以成像Bcr-Abl蛋白的新化合物。该化合物或其制药可接受的盐由以下式（I）表示。图5。
• AMIDE DERIVATIVE
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1533304B1

  公开（公告）日：2009-11-04
• Amide derivative
  申请人：Asaki Tetsuo

  公开号：US20060014742A1

  公开（公告）日：2006-01-19

  The present invention provides an amide derivative represented by the following general formula (1): wherein R 1 represents a saturated cyclic amino group, R 2 represents alkyl, halogen or haloalkyl, R 3 represents hydrogen or halogen, Het 2 represents pyridyl or pyrimidinyl, and Het 1 represents a group of the formula [6], or a salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.
• US7494997B2
  申请人：——

  公开号：US7494997B2

  公开（公告）日：2009-02-24
• Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
  作者：Tetsuo Asaki、Yukiteru Sugiyama、Taisuke Hamamoto、Masaya Higashioka、Masato Umehara、Haruna Naito、Tomoko Niwa

  DOI：10.1016/j.bmcl.2005.11.042

  日期：2006.3

  A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia. (C) 2005 Elsevier Ltd. All rights reserved.